Certificate of Analysis (COA) View the laboratory certificate for this product [ View COA ]

V.Med Semax 7000mcg nasal Spray

R 0.00
Add to WishlistCompare

V.MED Semax 7000 mcg — Lyophilised Peptide Nasal Spray

Product Description

Explore the science behind Semax with V.MED Semax 7000 mcg, a lyophilized peptide nasal spray presented in a 10 ml bottle.

Semax is a synthetic heptapeptide originally developed in Russia and investigated for its potential role in neurological research. Scientific interest has focused on neurotrophic signaling, cerebral ischaemia, and pathways associated with neurological function.

Semax has been studied in experimental models and small human studies, particularly in Russian clinical research. Although preliminary findings have generated interest in neuroprotection and cognitive function, further high-quality, independently replicated clinical trials are needed to establish its effectiveness and long-term safety.

Product Specifications

  • Brand: V.MED

  • Compound: Semax

  • Labelled strength: 7,000 mcg per bottle

  • Format: Nasal spray

  • Bottle volume: 10 ml

  • Formulation stated on packaging: Lyophilized peptide

  • Labelled delivery: 100 mcg per dose

  • Research category: Neurobiology and neurotrophic signaling

Main Research Areas

1. Neurotrophic signaling

Preclinical studies have investigated Semax in relation to brain-derived neurotrophic factor (BDNF) and other pathways associated with neuronal signaling and cellular responses.

These findings provide a basis for further research but do not establish improved cognitive performance in humans.

2. Neurological recovery research

Small Russian clinical studies have investigated Semax as an adjunct to standard care in patients experiencing ischaemic stroke. Some studies reported improvements in neurological recovery measures.

However, the evidence remains limited by study design, sample sizes, and a lack of independent replication. These findings do not establish Semax as a proven treatment for stroke or other neurological conditions.

3. Cognitive and memory-related research

Experimental research has explored potential relationships between Semax and neurological processes associated with learning, memory, and information processing.

Human evidence remains insufficient to establish reliable improvements in memory, attention, focus, or cognitive performance in healthy individuals.

4. Neuroprotective mechanisms

Laboratory and animal studies have explored potential effects on pathways associated with neuronal stress and injury. These findings are preliminary and cannot be assumed to translate into clinical benefits in humans.

Key Features

Semax peptide formulation — Contains Semax, a synthetic heptapeptide investigated in neurological and neurotrophin-signalling research.

7,000 mcg per bottle — Listed total Semax content for the whole bottle, not the amount per spray.

10 ml nasal spray format — Presented in a 10 ml bottle in nasal spray format.

100 mcg per labelled dose — The product listing specifies 100 mcg per dose. This specification is not a recommended dosing schedule.

Lyophilized peptide — Described in the listing as a lyophilized formulation. Consult the supplied product instructions for preparation, handling and storage requirements.

V.MED branded product — Identified in the product listing as V.MED Semax 7000 mcg.

Dosage & Usage
FAQ's & Tips

What is V.MED Semax 7000 mcg?

V.MED Semax is a Semax peptide product presented as a nasal spray in a 10 ml bottle. The product description lists 7,000 mcg of Semax per bottle and describes the formulation as a lyophilized peptide.

Does 7,000 mcg refer to each spray or the whole bottle?

The listed 7,000 mcg refers to the total amount per bottle, not each spray. The product description separately lists 100 mcg per labelled dose. This is product information, not a recommended dosing schedule.

What is Semax studied for?

Semax has been investigated in neurological research, including neurotrophic signalling, responses to neuronal stress, and processes associated with learning and memory. Research on the compound does not establish benefits for this finished V.MED product.

Is Semax proven to improve memory, focus or concentration?

The evidence described for this product is preliminary. Human research remains insufficient to establish reliable improvements in memory, attention, focus or cognitive performance in healthy individuals. Laboratory and animal findings should not be interpreted as guaranteed human benefits.

Can this product replace treatment for a neurological condition?

No. The research discussed in the listing does not establish this product as a proven treatment for stroke or other neurological conditions. Do not replace prescribed treatment or delay medical care on the basis of this product's research information.

Where can I find preparation, storage and use instructions?

Consult the instructions supplied with the product for preparation, storage and handling requirements. Do not assume that a product described as lyophilized is ready to use or choose a diluent based on general online guidance. If the supplied instructions are missing or unclear, contact Health Tech before use.

Research

Semax: Research Overview

Semax has been investigated in neurological research, including neurotrophin signalling and recovery after cerebral ischaemia. The studies below concern Semax as a compound, not the finished V.MED Semax 7000 mcg nasal spray. They do not establish this product's effectiveness, quality, bioavailability or long-term safety, and should not be used as dosing instructions.

1. Human study: rehabilitation after ischaemic stroke (2018)

Gusev and colleagues examined 110 patients after ischaemic stroke, grouped by early or late rehabilitation and whether they received Semax. Researchers assessed plasma brain-derived neurotrophic factor (BDNF), motor performance and the Barthel index, a measure of daily functioning. The authors reported increased plasma BDNF and improved functional recovery measures with Semax alongside rehabilitation.

Interpretation: This is a clinical signal in a specific stroke-rehabilitation setting, not evidence of improved memory or focus in healthy people. The abstract describes treatment subgroups but does not establish blinded, placebo-controlled randomisation. Its findings cannot be assumed to apply to this commercial formulation or replace standard stroke care.

Read the study abstract on PubMed: Semax at different stages of ischaemic stroke

2. Animal study: neurotrophin signalling after experimental ischaemia (2011)

Researchers examined Semax and its C-terminal peptide Pro-Gly-Pro in rats after bilateral common carotid artery occlusion, an experimental model of reduced blood supply to the brain. They measured expression of neurotrophins, including Bdnf, Ngf and Nt-3, and their receptors in several brain regions. Semax altered gene-expression responses, particularly in the frontal cortex and hippocampus, and counteracted some ischaemia-associated reductions in expression.

Interpretation: These findings help explore possible biological mechanisms. Changes in gene expression in an animal model do not establish clinical neuroprotection, cognitive enhancement or safety in humans.

Read the original paper: Semax and neurotrophin expression in rat brain during incomplete global ischaemia

3. Earlier exploratory clinical research: acute ischaemic stroke

An earlier clinical and electrophysiological study investigated Semax in 30 patients during the acute phase of hemispheric ischaemic stroke, including monitoring of brain function with EEG. This research concerns Semax within a clinical stroke-treatment setting, rather than routine use for concentration or general wellbeing.

Interpretation: A small clinical study is not sufficient on its own to establish effectiveness or long-term safety. It also does not validate the finished V.MED product or justify substituting it for medical treatment.

Read the study abstract on PubMed: Semax in acute hemispheric ischaemic stroke

Reviews